E Merck has launched Livogen Z, in the market with zinc sulphate.Livogen Z is one of the three versions of the trademark haematinic drug
E Merck has launched Livogen Z, in the market with zinc sulphate.Livogen Z is one of the three versions of the trademark haematinic drug Livogen.Livogen was an old product of Glaxo India with Rs 3 crore revenue.Glaxo India Ltd has sold its Livogen brand to E Merck India Ltd.
According to a notification sent to the Bombay Stock Exchange (BSE), Glaxo India signed a memorandum of understanding with E Merck India, selling all the rights, title and interest in the registered trademark Livogen. This Mumbai based company, E Merck had purchased Livogen from Glaxo India Ltd for Rs 8 crore. The plain Livogen tablet as well as the Livogen Z tablet are available in the market.E Merck had introduced the tonic version of Livogen Z even before the tablets. E Merck will have only one version of Livogen Z and it will contain zinc sulphate. Zinc decreases tubal defects in pregnant women.The launch of this drug was delayed, as E Merck had to take Karnataka Food and Drugs control Administration's permission to change the composition of the drug. E Merck is believed to have added zinc sulphate to Livogen Z as they felt it was unethical to sell otherwise.
